<DOC>
	<DOCNO>NCT00768274</DOCNO>
	<brief_summary>The purpose study investigate oral formulation RVX000222 safety , pharmacokinetic efficacy healthy subject .</brief_summary>
	<brief_title>Safety , Pharmacokinetic Study RVX000222 Healthy Subjects Subjects With Low HDL Cholesterol</brief_title>
	<detailed_description>One-third US population , almost 80 million adult , cardiovascular disease mortality associate heart disease still remain leading cause death around world . The major risk factor cardiovascular disease associate atherosclerosis dyslipidemia , characterize high level low density lipoprotein ( LDL ) and/or low level high density lipoprotein ( HDL ) . HDL well establish role atherosclerosis cardiovascular disease protection . HDL mediate removal cholesterol atherosclerotic plaque elimination body . The major component HDL consist apolipoprotein A-I ( ApoA I ) . Recent intervention study synthetic HDL particle recombinant ApoA-I show HDL capacity reverse coronary atherosclerosis . RVX000222 member novel class small molecule candidate treatment dyslipidemia increase plasma level ApoA-I HDL .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Subjects meet follow criterion may enrol : 1 . Be men woman 18 65 year old , inclusive 2 . Weigh 60 kg 110 kg , inclusive , BMI ≥25 kg/m2 . 3 . Healthy volunteer normal low HDL 4 . If female , nonpregnant ( determined negative serum pregnancy test Screening ) , nonlactating , childbearingpotential willing practice acceptable form birth control . If male , willing practice acceptable form birth control . Subjects meet follow criterion enrol : 1 . Have presently , history , clinically significant disease , include cardiovascular , gastrointestinal , renal , hepatic , pulmonary , endocrine , hematologic , vascular , immunologic , metabolic , neurological , collagen disease , judge Investigator . 2 . Have active cholecystitis gallbladder symptom within 60 day prior Checkin ( subject cholecystectomy exclude study ) . 3 . Have clinically significant illness , opinion Investigator , within 30 day prior Checkin . 4 . Have hypertension currently treat , uncontrolled hypertension 5 . Have serum creatinine &gt; 1.5 mg/dL , hemoglobin &lt; 11.2 g/dL , white blood cell count &lt; 4000/μL . 6 . Have positive test result HIV , hepatitis A , B , C. 7 . Have positive result drug screen test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Cholesterol</keyword>
	<keyword>High density lipoprotein</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Apolipoprotein A-I</keyword>
</DOC>